Pantesin® Pantethine featured in Wall Street Journal

In an article appearing December 3, 2012 in the Wall Street Journal, Pantesin®  was called "an interesting new approach in an era in which we are looking for alternatives for people" who can't tolerate statins, by Vincent Bufalino, an American Heart Association spokesman. The article also discusses the cholesterol lowering results of a recent 120-patient North American study, and also mentions a 2005 published review of 28 clinical trials that support Pantesin's minimal side effects.

Read the full article on The Wall Street Journal